Professor Adnan Khattak is a Medical Oncologist with special interest in gastrointestinal / hepatobiliary cancers, melanoma and lung cancer. In addition to his private practice, he works as a Consultant Medical Oncologist at Fiona Stanley Hospital (FSH) where he is also the Director at Fiona Stanley Hospital Cancer Clinical Trials Unit.
Background & Training
Dr Khattak did his initial specialist training at The Queen Elizabeth Hospital and Flinders Medical Centre in Adelaide before going to the UK. He worked as a Clinical Research Fellow at the Royal Marsden Hospital in London. He received his Fellowship in Medical Oncology in 2013 and started working as a Consultant at Royal Perth Hospital before transitioning to FSH in 2015. He looks after his private patients at Hollywood Private Hospital.
Dr Khattak is an active researcher, with interests in colorectal cancer, melanoma and cancer immunotherapy. He is the the Primary Investigator of many International Clinical Trials. He is the pioneer of early drug development (Phase 1) work at Fiona Stanley Hospital and now leads the largest trials unit in Perth South Metro. He is also involved with a number of clinical trials at Hollywood Private Hospital.
He has more than 60 publications at this stage in various peer-reviewed journals including the New England Journal of Medicine, the Lancet Oncology, JAMA Oncology, Journal of Clinical Oncology and European Journal of Cancer. He has also co-authored the National Health & Medical Research Council (NHMRC) guidelines for the management of advanced colorectal cancer.
He has presented his research at a number of National and International scientific meetings. He has been invited as an International visiting speaker to Hong Kong, Taiwan, Saudi Arabia, China, Singapore and India. His current research projects include blood-based biomarkers (circulating tumour cells and circulating tumour DNA) of response & resistance to immunotherapy in cancer (lung, GI & melanoma). He is also leading an early stage bowel cancer translational research project (Notch pathway) aimed at identifying patients at high risk of disease relapse and those that are less likely to benefit from post-operative chemotherapy.
He is the recipient of a number of prestigious research awards including Cancer Council WA Suzanne Cavanagh Young Investigator Award, Spinnaker Health Research Foundation Collaborative research grant, MSD Young Investigator award, NHMRC Developmental grant and Royal Perth Hospital Medical Research Foundation Award. He was also awarded the Raine Foundation translational research fellowship in 2019. He is the Chief Investigator/Associate Investigator of research grants in excess of A$2,500,000.